Published in Exp Hematol on February 01, 2008
Myeloproliferative disorders. Blood (2008) 3.37
Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol (2009) 1.06
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood (2013) 0.99
The bone marrow stroma in hematological neoplasms--a guilty bystander. Nat Rev Clin Oncol (2011) 0.89
Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. Blood (2009) 0.87
Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury. Hepatol Res (2014) 0.85
Evidence for organ-specific stem cell microenvironments. J Cell Physiol (2010) 0.81
CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. J Cell Physiol (2010) 0.81
Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Mod Pathol (2012) 0.79
C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol (2014) 0.79
CD133 marks a stem cell population that drives human primary myelofibrosis. Haematologica (2015) 0.78
Increased differentiation of dermal mast cells in mice lacking the Mpl gene. Stem Cells Dev (2009) 0.77
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. Oncotarget (2016) 0.76
Stem cells and bone diseases: new tools, new perspective. Bone (2014) 0.76
Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. Platelets (2013) 0.75
Rational therapeutic options for patients with myeloproliferative neoplasms. Trans Am Clin Climatol Assoc (2011) 0.75
CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget (2016) 0.75
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 19.60
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature (2000) 16.75
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 11.41
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity (2006) 11.28
Myelofibrosis with myeloid metaplasia. N Engl J Med (2000) 7.04
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med (2005) 7.01
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol (2002) 6.22
Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest (2000) 3.78
Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol (2002) 3.61
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest (2003) 3.52
Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood (2002) 3.06
Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem (2001) 3.03
Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood (2001) 3.01
Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood (2004) 2.80
The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia (2002) 2.79
Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood (1999) 2.61
A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A (1997) 2.55
Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol (1999) 2.52
Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family. Proc Natl Acad Sci U S A (1989) 2.24
Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest (2002) 2.22
Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity (2003) 2.10
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci U S A (1999) 1.97
Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol (2005) 1.90
Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol (2002) 1.82
Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood (2003) 1.72
Leukocyte elastase negatively regulates Stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem (2002) 1.63
Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood (2002) 1.60
Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem (2004) 1.51
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells (2006) 1.41
Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res (2003) 1.39
Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol (2001) 1.36
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood (2005) 1.35
Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood (2000) 1.32
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol (1999) 1.29
The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood (1990) 1.27
Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood (2000) 1.26
Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood (2000) 1.19
Bone marrow homing: the players, the playfield, and their evolving roles. Curr Opin Hematol (2003) 1.18
Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood (2004) 1.15
The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp Hematol (2005) 1.15
The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood (2006) 1.13
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis (2007) 1.12
Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp Hematol (2004) 1.11
The role of osteoblasts in the hematopoietic microenvironment. Stem Cells (1998) 1.09
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood (2005) 1.06
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood (2002) 1.06
Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. Exp Hematol (2007) 1.05
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res (2007) 1.04
p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res (2005) 1.02
Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells (2002) 1.00
Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds. Blood (2005) 0.91
Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis. Acta Haematol (1997) 0.88
Differential amplification of murine bipotent megakaryocytic/erythroid progenitor and precursor cells during recovery from acute and chronic erythroid stress. Stem Cells (2005) 0.88
Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1. J Biol Chem (2006) 0.85
Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. Am J Clin Pathol (2005) 0.82
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol (2003) 3.45
Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell (2013) 3.31
Challenges and successes in developing new therapies for hepatitis C. Nature (2005) 3.22
Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood (2002) 3.06
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J Biol Chem (2003) 2.72
Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature (2002) 2.68
Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol (2003) 2.63
NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature (2013) 2.63
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol (2003) 2.55
Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology (2002) 2.49
Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity (2009) 2.44
Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet (2003) 2.43
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood (2008) 2.16
Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science (2008) 2.10
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Helical myofiber orientation after myocardial infarction and left ventricular surgical restoration in sheep. J Thorac Cardiovasc Surg (2005) 2.06
GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J Exp Med (2003) 1.96
Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin. Blood (2006) 1.95
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother (2004) 1.94
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood (2014) 1.87
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 1.76
A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. Biophys J (2007) 1.74
EVI1 induces myelodysplastic syndrome in mice. J Clin Invest (2004) 1.72
Combinatorial and distinct roles of α₅ and α₄ integrins in stress erythropoiesis in mice. Blood (2010) 1.72
Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol (2004) 1.71
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70
MicroRNA expression dynamics during murine and human erythroid differentiation. Exp Hematol (2007) 1.67
Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest (2002) 1.63
Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood (2002) 1.60
Functional MICA-129 polymorphism and serum levels of soluble MICA are correlated with ulcerative colitis in Chinese patients. J Gastroenterol Hepatol (2011) 1.56
Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med (2006) 1.56
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood (2004) 1.55
Periodic reversal of direction allows Myxobacteria to swarm. Proc Natl Acad Sci U S A (2009) 1.55
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem (2006) 1.55
Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem (2005) 1.54
The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood (2011) 1.50
Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res (2003) 1.50
A hierarchical model for estimating response time distributions. Psychon Bull Rev (2005) 1.50
Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology (Williston Park) (2013) 1.49
Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood (2009) 1.48
A unique role for the host ESCRT proteins in replication of Tomato bushy stunt virus. PLoS Pathog (2009) 1.47
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica (2005) 1.44
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood (2006) 1.42
3D fiber tractography with susceptibility tensor imaging. Neuroimage (2011) 1.39
Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. Blood (2005) 1.37
Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology (2008) 1.36
Hierarchical classification of protein folds using a novel ensemble classifier. PLoS One (2013) 1.36
Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell (2012) 1.35
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood (2005) 1.35
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res (2012) 1.35
Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res (2010) 1.34
Determinants of aflatoxin levels in Ghanaians: sociodemographic factors, knowledge of aflatoxin and food handling and consumption practices. Int J Hyg Environ Health (2006) 1.34
Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood (2005) 1.32
Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci U S A (2002) 1.32
Quantitative comparison of myocardial fiber structure between mice, rabbit, and sheep using diffusion tensor cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2011) 1.31
VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin. Blood (2005) 1.30
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood (2012) 1.26
Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol (2009) 1.26
A three-dimensional model of myxobacterial aggregation by contact-mediated interactions. Proc Natl Acad Sci U S A (2005) 1.26
Social interactions in myxobacterial swarming. PLoS Comput Biol (2007) 1.24
Screening of the yeast yTHC collection identifies essential host factors affecting tombusvirus RNA recombination. J Virol (2006) 1.23
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood (2010) 1.23
The use of India ink in tissue-simulating phantoms. Opt Express (2010) 1.23
Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol (2009) 1.23
Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nat Commun (2012) 1.21
Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. J Immunol (2002) 1.21
Erythroid cells in vitro: from developmental biology to blood transfusion products. Curr Opin Hematol (2009) 1.20
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood (2008) 1.20
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood (2013) 1.19
Surgical management of complications after hearing aid fitting. Laryngoscope (2004) 1.19
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol (2007) 1.19
Globin phenotype of erythroid cells derived from human induced pluripotent stem cells. Blood (2010) 1.19
Semantic and subword priming during binocular suppression. Conscious Cogn (2009) 1.19